Curis Says Roche Submits IND Application For Phase 2 Study Of Erivedge

(RTTNews) - Curis, Inc. (CRIS), an oncology-focused biotechnology company said Roche Holding AG (RHHBY) has filed an Investigational New Drug or IND application with the U.S. Food and Drug Administration or FDA to start a multicenter, Phase 2 clinical trial of Erivedge in patients with idiopathic pulmonary fibrosis or IPF, a chronic debilitating lung disease. Roche and Genentech, a member of the Roche Group (ROG.SW, RO.SW) develop and commercialize Erivedge under a collaboration agreement with Curis.

Ali Fattaey, president and chief executive of Curis, said: "...IPF represents a serious unmet medical need and patients suffering from this disease are in need of improved treatment options."